Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
03
2020
accepted:
21
05
2020
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
26
8
2020
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) has seen increasing use as a prostate cancer treatment in recent years and has proven medically effective in numerous contexts. The treatment, however, is associated with a host of side effects including depression. Managing the psychological wellbeing of prostate cancer patients is important for maximizing their survival outcomes. Thus, this study aimed to evaluate depressive symptomatology in patients with androgen deprivation therapy (ADT) compared with that in patients who underwent prostatectomy and to explore the factors that affect depressive symptoms, which might occur during ADT. One hundred and seven patients undergoing ADT (ADT group) and prostatectomy (Operation group) were enrolled. Adjustments were made for differences in characteristics between groups using a propensity score model with stabilized weights before treatment. Depressive symptoms between groups were compared using the Beck Depression Inventory (BDI) before treatment and six months after treatment initiation. To identify factors affecting depressive symptoms during ADT, multivariate regression analysis was performed on the mean change in BDI score, age, body mass index, testosterone level, prostate-specific antigen level, the international index of erectile function (IIEF), and the Gleason score. The BDI score significantly increased in the ADT group compared to the operation group six months after treatment initiation (p < 0.001). Multivariate regression analysis revealed that before ADT, the BDI score was higher by 0.446 according to the IIEF. During ADT, the BDI score increased by 1.579 according to changes in BMI (p = 0.021) and decreased by 0.01 according to changes in testosterone levels (p = 0.034). Depressive symptoms can be exacerbated in prostate cancer patients undergoing ADT. Efforts are needed to diagnose and treat depression appropriately, especially if depressive symptoms change in ADT patients with a high IIEF score before ADT, or reduced testosterone levels or increased BMI during ADT.
Identifiants
pubmed: 32542009
doi: 10.1371/journal.pone.0234264
pii: PONE-D-20-06902
pmc: PMC7295190
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234264Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Biosci. 2007 Sep 01;12:4957-71
pubmed: 17569623
Int Urol Nephrol. 2016 Apr;48(4):517-27
pubmed: 26781653
Oncol Nurs Forum. 2005 May 10;32(3):545-56
pubmed: 15897931
J Am Board Fam Pract. 1995 Jul-Aug;8(4):317-20
pubmed: 7572297
Urol Oncol. 2008 Mar-Apr;26(2):141-6
pubmed: 18312932
Cancer. 2005 Apr 15;103(8):1615-24
pubmed: 15742331
J Clin Oncol. 2007 Apr 20;25(12):1596-605
pubmed: 17404365
Neuroscience. 2010 Feb 3;165(3):850-62
pubmed: 19909795
Psychooncology. 2015 Apr;24(4):472-7
pubmed: 24924331
Psychol Bull. 2008 Jan;134(1):1-30
pubmed: 18193993
BJU Int. 2011 Mar;107(6):924-8
pubmed: 20860651
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
BJU Int. 2005 Apr;95(6):780-5
pubmed: 15794782
Urology. 2004 Apr;63(4):742-5
pubmed: 15072892
Cancer. 2012 Apr 1;118(7):1940-5
pubmed: 22009684
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1;38(1):103-111
pubmed: 28593888
Int J Endocrinol. 2012;2012:280724
pubmed: 22719760
Asian J Androl. 2012 Mar;14(2):226-31
pubmed: 22231296
Psychooncology. 2013 Jun;22(6):1328-35
pubmed: 22855322
BMJ Open. 2015 Nov 30;5(11):e007618
pubmed: 26621509
Support Care Cancer. 2009 May;17(5):509-17
pubmed: 18719947
Clin Pract Epidemiol Ment Health. 2007 Feb 08;3:2
pubmed: 17288583
Value Health. 2010 Mar-Apr;13(2):273-7
pubmed: 19912596
Urol J. 2018 May 03;15(3):104-108
pubmed: 29388185
BJU Int. 2008 Jul;102(1):44-7
pubmed: 18336606